Eli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created local biotech company called BioCritica that will seek to reinvigorate sales of the medication.
Warsaw-based Zimmer Holdings Inc. has enjoyed eight years as the giant in the industry of selling knee- and hip-replacement implants to hospitals. But now it faces a challenge from Johnson & Johnson.
Industry cluster in northern Indiana has adapted to every other change in health care, and will absorb tissue regeneration, too.
Shares of Endocyte Inc. have doubled since the company’s initial public offering in February—even though the common wisdom is it won’t see sales from its first cancer drug until 2014.
Profits flowing from earlier investments could mean more available capital, but firms continue to be selective in placing their bets.
Warsaw-based orthopedic implant maker Zimmer Holdings Inc. said Thursday its first-quarter profit rose 2 percent on higher sales of reconstructive, dental and other products.
Indianapolis-based Dow AgroSciences on Thursday reported sales of $1.6 billion in its first quarter, up 17 percent from the same period last year due to higher volume and increased prices.
California-based Hycor Biomedical Inc. plans to move its headquarters to central Indiana, creating as many as 20 jobs in the next two years, state economic development officials announced Wednesday morning.
Roche Diagnostics Corp. won regulatory approval for a new HPV test, giving it a technological edge in the $300 million market for automated cervical cancer tests.
Carl Cook has been tabbed to replace his father, Bill Cook, who died a week ago. But many in the Bloomington business community know little about him, which reflects the company’s strict privacy policy.
Eli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed pancreas drug before it resubmits an application to have the drug approved for sale.
The drug awaits final action by the European Commission, which has the authority to approve medicines for the European Union. The Commission usually makes a decision on CHMP recommendations within two to three months.
The total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown Bioscience is one-third of that, said a company executive.
TechPoint-led initiative is meant to help bring inventions to market by giving them a trial in real-world setting.
The Metropolitan Development Commission on Wednesday preliminarily approved Advion BioServices Inc.’s request for a tax abatement to build a laboratory at Purdue Research Park in Indianapolis.
Advion, a provider of bioanalytical research and a subsidiary of Ithaca, N.Y.-based Advion BioSciences Inc., is expected to open the 22,000-square-foot lab in mid-May with 49 employees, according to the company’s application.
Northern Indiana's Manchester College plans to begin work this summer on the college's new $18 million pharmacy school.
The widespread Internet posting of a letter by a retired Purdue University researcher who says he has linked genetically modified corn and soybeans to crop diseases and to abortions and infertility in livestock has raised concern among scientists that the public will believe his unsupported claim is true.
The Warsaw-based maker of orthopedic implants has filed suit to stop a Detroit-area law firm from making allegedly false claims and using its trademarks on websites designed to attract plaintiffs to sue Zimmer over one of its knee-replacement implants called NexGen.
The founder of Bloomington-based life sciences giant Cook Group Inc. and the wealthiest man in Indiana leaves a legacy of dozens of historic structures saved from decay or demolition. He also was a major donor to Indiana University and its athletics department.
